The Glasgow Prognostic Score as a Predictor of Survival after Chemoradiotherapy for Limited-Disease Small Cell Lung Cancer
Oncology · 2024
DOI: 10.1159/000540651 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, 2024. Verfasst von Satoshi Endo und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota, Japan. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Chemoradiotherapy, C-Reactive Protein. Die Arbeit nennt 43 Literaturangaben.
Abstract (Originalsprache)
Introduction
Established biomarkers for predicting chemoradiotherapy efficacy for limited-disease small cell lung cancer (LD-SCLC) are lacking. The inflammation-based Glasgow Prognostic Score (GPS), comprising serum C-reactive protein (CRP) and albumin levels, can predict survival in advanced cancer. This study investigated whether metabolic and inflammatory markers, including the GPS, can predict the efficacy of chemoradiotherapy in patients with LD-SCLC.
Methods
We retrospectively analyzed 124 patients who underwent chemoradiotherapy for LD-SCLC at two institutions between April 2007 and June 2021, and assessed the prognostic significance of various metabolic and inflammatory markers. The GPS was calculated using the CRP and albumin concentrations, and categorized as follows: 0, CRP <1.0 mg/dL and albumin ≥3.5 mg/dL; 1, elevated CRP or decreased albumin; and 2, CRP ≥1.0 mg/dL and albumin<3.5 mg/dL. Differences in progression-free survival (PFS) and overall survival (OS) were examined using Kaplan-Meier curves and Cox proportional-hazard models.
Results
The overall response rate was 95.1% (95% confidence interval [CI]: 89.6–97.9%). The median PFS and OS from chemoradiotherapy initiation were 12.6 (95% CI: 9.9–15.4) and 29.0 (95% CI: 24.8–45.5) months, respectively. The GPS demonstrated independent predictive ability for the effectiveness of chemoradiotherapy, wherein favorable scores (GPS 0–1) were significantly correlated with superior PFS and OS compared to unfavorable scores (GPS 2: PFS: 14.8 vs. 6.7 months, p = 0.0001; OS: 35.4 vs. 11.0 months, p < 0.0001).
Conclusion
This preliminary examination revealed that the GPS was significantly associated with PFS and OS in patients undergoing chemoradiotherapy for LD-SCLC, indicating its potential utility in assessing the therapeutic outcomes in LD-SCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota, Japan.
- Department of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.
- Division of Radiation Oncology, Gunma Prefectural Cancer Center, Ota, Japan.
- Department of Radiation Oncology, International Medical Center, Saitama Medical University, Saitama, Japan.
- Division of Health Evaluation and Promotion, SUBARU Health Insurance Society, Ota Memorial Hospital, Ota, Japan.
Zitieren
APA
Endo, S., Imai, H., Shiono, A., Hashimoto, K., Miura, Y., Okazaki, S., Abe, T., Mouri, A., Kaira, K., Masubuchi, K., Masubuchi, T., Kobayashi, K., Minato, K., Kato, S., & Kagamu, H. (2024). The Glasgow Prognostic Score as a Predictor of Survival after Chemoradiotherapy for Limited-Disease Small Cell Lung Cancer. Oncology. https://doi.org/10.1159/000540651
Vancouver
Endo S, Imai H, Shiono A, Hashimoto K, Miura Y, Okazaki S, et al. The Glasgow Prognostic Score as a Predictor of Survival after Chemoradiotherapy for Limited-Disease Small Cell Lung Cancer. Oncology. 2024. doi:10.1159/000540651
BibTeX
@article{Endo2024,
author = {Endo, Satoshi and Imai, Hisao and Shiono, Ayako and Hashimoto, Kosuke and Miura, Yu and Okazaki, Shohei and Abe, Takanori and Mouri, Atsuto and Kaira, Kyoichi and Masubuchi, Ken and Masubuchi, Takeshi and Kobayashi, Kunihiko and Minato, Koichi and Kato, Shingo and Kagamu, Hiroshi},
title = {The Glasgow Prognostic Score as a Predictor of Survival after Chemoradiotherapy for Limited-Disease Small Cell Lung Cancer},
journal = {Oncology},
year = {2024},
doi = {10.1159/000540651}
}
EUVIMED